AbDiffuser: full-atom generation of in vitro functioning antibodies
Preprint| Поле | Значение |
|---|---|
| Authors | NR |
| Year | 2023/2024 |
| Venue / status | arXiv preprint (Frontier/Watchlist) |
| DOI | 10.48550/arXiv.2308.05027 |
| URL | https://arxiv.org/abs/2308.05027 |
| Preprint URL | https://arxiv.org/abs/2308.05027 |
| Tools | AbDiffuser |
Задача и claimed novelty
| Поле | Значение |
|---|---|
| Main biological task | Full-atom antibody sequence–structure generation with length changes |
| Claimed novelty | NR |
Архитектура
| Поле | Значение |
|---|---|
| Model architecture | Equivariant physics-informed diffusion with aligned antibody priors |
| Input representation | NR |
| Encoder / decoder | NR |
| Generative state | Full-atom antibody sequence + structure |
| Conditioning | Antibody priors; sequence-length variation |
| Sampling | NR |
Training
| Поле | Значение |
|---|---|
| Objectives / losses | NR |
| Dataset | NR |
| Preprocessing | NR |
Inference
NR
Baselines и retrospective benchmarks
| Поле | Значение |
|---|---|
| Baselines | NR |
| Retrospective | NR |
Prospective experimental validation
| Поле | Значение |
|---|---|
| Prospective | Prospective HER2 binding and expression; publication remains preprint |
| Tested designs | 16 HER2 antibody designs expressed; 57.1% of selected designs reported as tight binders |
| Success criterion | Prospective HER2 binding and expression; publication remains preprint |
| Main results | Prospective HER2 binding and expression; publication remains preprint |
Limitations
Preprint and no verified implementation; selected-design success rate is selection-conditional and target-specific.
Что статья показывает
- Prospective HER2 binding and expression; publication remains preprint
Чего статья не показывает
- Predicted confidence, likelihood, pLDDT, docking or developability scores are not experimental affinity.
Размеченные утверждения
| Утверждение | Тип | Локатор |
|---|---|---|
| AbDiffuser: full-atom generation of in vitro functioning antibodies | Interpretation | DOI/URL from landscape matrix |
| Publication status: arXiv preprint (Frontier/Watchlist) | Author-reported | landscape matrix, publication status column |
Review queue
- Bibliographic title must be verified against the PDF.
- Official repository/service not verified.
Source-grounded разбор статьи
Исследовательский вопрос
[MATRIX]Full-atom antibody sequence–structure generation with length changes
Утверждения и поддержка evidence
[MATRIX]Claimed novelty: NR
[INTERPRETATION]Статья не «доказывает» общее преимущество метода вне своего экспериментального дизайна.
Что представленный evidence не поддерживает
- Predicted confidence, likelihood, pLDDT, docking or developability scores are not experimental affinity.
Ограничения, признанные авторами
[MATRIX]Preprint and no verified implementation; selected-design success rate is selection-conditional and target-specific.
Дополнительные ограничения интерпретации
NRПока Methods/SI не прочитаны, нельзя утверждать split leakage, точные гиперпараметры и полноту ablation.